Additionally, IL28B polymorphisms have been reported to be predictive for transition to cirrhosis [21], fibrosis [22], hepatocellular carcinoma [23],[24], and potentially to influence clinical responses in HBV infection [25], HAV infection [26] and glucose metabolism in type 2 diabetes [27]. Here, IFNL3 is linked to hepatocellular carcinoma.